IMBRUVICA® (ibrutinib) – New Formulation
Available For Prescription Order Today!
Onco360 has been selected to the extremely limited distribution network of
Specialty Pharmacies for IMBRUVICA (ibrutinib).
Refer Your IMBRUVICA Patients to Onco360
The New IMBRUVICA® pill is now available as a one pill, once a day treatment. The new IMBRUVICA is the same medication, at the same dose, with the same active ingredient. For most of your patients, this will mean taking fewer pills a day.
3 easy ways to order IMBRUVICA.
e-Prescribe to Onco360 in Louisville, KY 40223, or NPI# 1437577988 under the retail tab in your EMR/EHR or standalone e-prescribing application.
IMBRUVICA (ibrutinib) has been approved by the FDA for the four following indications and is available for prescription order through Onco360
|APPROVED INDICATIONS1||RECOMMENDED DOSAGE2|
|Chronic lymphocytic leukemia (CLL) patients||420 mg orally once daily|
|CLL patients with 17p deletion||420 mg orally once daily|
|Waldenström’s macroglobulinemia (WM) patients||420 mg orally once daily|
|Mantle cell lymphoma (MCL) patients who have received
at least one prior treatment
|560 mg orally once daily|
|Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy||560 mg taken orally once daily|
For more information about IMBRUVICA, please visit IMBRUVICA.com.
- Imbruvica Prescribing Information
All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.